Archive | March, 2011

Decent Follow Through From Yesterday’s Biotech Rally

Biopharmaceutical stocks caught bids today (in a weak technology market) after yesterday’s M&A spiked rally. Large cap leaders in the NASDAQ-100 were up: Biogen(BIIB) up 1.63%, Celgene (CELG) up 1.6% and Gilead (GILD) up 0.68%. Major ETF’s-IBB FBT XBI- also gained about 0.5%.Amgen(AMGN) was flat at $53.84. In the Rayno Portfolio: Diagnostic products maker for […]

Continue Reading 0

Caution on Optimer (OPTR) Down 3% in Strong Biotech Market-update April 1 OPTR up 11%

Optimer  soars 11% to $13.13 on presentation of Shea Data and preliminary FDA review: Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients – Yahoo! Finance Optimer Rises After FDA Staff Says Antibiotic Is Effective – Bloomberg Optimer is selling off late at the close […]

Continue Reading 0

Biotech Sector Soars On Valeant (VRX) Bid For Cephalon (CEPH)

Biopharmaceutical  Stocks Ignited By M&A Potential M&A has been a key driver for investing in biotech stocks as need for product pipeline and technologies grows. The drug development process is slow and synergies can be found faster by buying companies on the open market. New drugs require more than $1B of investment over a 10 […]

Continue Reading 0

Rayno Life Science Portfolio: Cephalon (CEPH) Up 27% After Hours on Valeant (VRX) Hostile Bid- UPDATE

3/30/11 Update CEO Michael Pearson of Canadian based Valeant (VRX) reiterated his determination(live on CNBC this am) for buying Cephalon (CEPH) after being stalled by the Board of CEPH after initial discussions.Mr. Pearson stated he wanted to move quickly and if the deal stalls he would withdraw his bid for the Company.It is possible that […]

Continue Reading 0

Rayno Life Science Portfolio Up 1.3% In A Strong NASDAQ Market

As has been the pattern lately biotech sector rallies coincide with NASDAQ with the NAZ (2753) up 20.2 or 0.81% . The mid caps are the sweet spot in the market with as our mid-cap index of 33 biotechs are almost all green with the average up 1.57%. 14 of the stocks are up 2% […]

Continue Reading 0

Technology Convergence in Healthcare: Abbott (ABT), Alere (ALR) and Merge (MRGE)

In January we reported from the JPMorgan Healthcare Conference regarding convergence of communications and medical technologies. Two trends mentioned were use of cloud computing and connectivity in medicine. Here is a brief update: Abbott (ABT $48) announced today that the FDA cleared its i-Stat(R) 1 Wireless Point of Care (POC) Testing  System for real time […]

Continue Reading 0

Ariad (ARIA) and MolecularMD Collaborate in Companion Dx for CML

Ariad (ARIA $7.24 up 4.3%) continues to roll on today on heavy volume up 17% over 5 days on speculation, news and upgrades with strong expectations for their chronic myeloid leukemia drug ponatinib. Articles from Motley Fool, Seeking Alpha and The Street.com have spotlighted the  Company and potential news at the ASCO Meeting which is […]

Continue Reading 0

Why is the Market Going Up?

Rick Santelli on CNBC answered the question today. Very few places to put your money: 1-In the mattress-cash. 2-In the ground-metals, energy. 3-In equities-earnings. With investors worried about interest rates rising and  potentially no QE 3 , money could come out of bonds. In the WSJ today the data shows $7.84B out of Money-Market Assets […]

Continue Reading 0

Stocks to Watch-Life Science Tools and Diagnostics: Meridian(VIVO) and IRIS

On robust and active Life Science trading day two laggard diagnostic stocks perked up: Iris International (IRIS $9.41) is up 4.44% on FDA clearance of its iChem Velocity Workstation for automated Urine Chemistries. The stock is been trading from $9-10 over the past six months.P/S for 2011 forecasts is 165/119 or 1.39X. Felti and Co. […]

Continue Reading 0

Biotechs Bounce With Good NASDAQ Tape: Ariad(ARIA), Exelixis(EXEL)andOptimer(OPTR)

Biotech rally day with speculative news: ASCO,M&A,and Clinical News. Biotech stocks were green across the board with our mid-cap index of 33 stocks up 1%. ETF’s were strong: FBT up 1.3%, IBB up 1.3% and XBI up 1.45%. The NAZ is up 1.11%. Some notable winners are: Ariad (ARIA $6.80) up 7.7% on heavy volume, […]

Continue Reading 0